Dishing The Science with Dr. Sue

First GLP1 in a pill to reduce cardiovascular events in people with type 2 diabetes

Dr. Sue Pedersen

We know that several INJECTABLE GLP1 receptor agonists reduce cardiovascular events in people with type 2 diabetes. Now published is the first study ever to show that a GLP1 in a PILL can reduce cardiovascular events as well. Read on to learn more!

Learn more: https://drsue.ca/2025/04/first-glp1-in-a-pill-to-reduce-cardiovascular-events-in-people-with-type-2-diabetes/

Any medical discussion on this podcast is intended to be of a general nature only, and is intended for a Canadian audience. This podcast is not designed to give specific medical advice to patients, nor to their health care providers. If you have a medical problem you should consult your own physician for advice specific to your own situation. Postings on this podcast represent the personal opinions of Dr. Sue Pedersen. They are not representative of, nor endorsed by, Alberta Health Services. This podcast is intended for the Canadian general public as well as Canadian allied health professionals.

People on this episode